Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 14, 2014

View Archived Issues

MiniVax and University of Rochester enter into option agreement for antibody against pneumonia

Daiichi Sankyo aims to expand pipeline through collaboration with Virtici and Celdara Medical

Zymeworks and ImClone Systems to develop bispecific antibodies

FORMA Therapeutics advances cancer collaboration with Boehringer Ingelheim

Discovery of a novel compounds for the treatment of multidrug-resistant tuberculosis

Acetylon presents results from early clinical trials of ACY-1215 in multiple myeloma

Researchers present results and collaboration agreement on Bordetella pertussis vaccine technology

Development of a water-tight light-activated surgical adhesive for minimally invasive tissue repair

Alnylam acquires Sirna Therapeutics

AnaptysBio developing first-in-class anti-IL-33 therapeutic antibody

FDA accepts idelalisib NDA for refractory indolent NHL

Phase II study of CRLX-101 in ovarian cancer meets primary endpoint

EMA accepts Biovest's MAA for BiovaxID

Enanta Pharmaceuticals begins phase I study of EDP-788

Fibrocell Science and Intrexon expand collaboration

AstraZeneca patents detail novel BACE1 inhibitors

Actelion Pharmaceuticals divulges chemokine CXCR7 receptor agonists

Roche reports development of LPA1 receptor antagonists

Monoclonal antibody Hu3F8 receives FDA orphan drug status for osteosarcoma

Jazz Pharmaceuticals acquires rights to ADX-N05 from Aerial BioPharma

Alexion and Moderna enter agreement to develop mRNA Therapeutics for rare diseases

Lilly acquires a CGRP antibody for migraine prevention from Arteaus Therapeutics

Merck & Co. begins rolling submission of BLA for MK-3475

Phase II trial shows APG-101 prolongs overall survival in glioblastoma patients

Cubist files application to conduct first-in-human study of CB-618 in the Netherlands

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...